PT - JOURNAL ARTICLE AU - Hespe, Sophie AU - Waddell, Amber AU - Asatryan, Babken AU - Owens, Emma AU - Thaxton, Courtney AU - Adduru, Mhy-Lanie AU - Anderson, Kailyn AU - Brown, Emily E. AU - Hoffman-Andrews, Lily AU - Jordan, Elizabeth AU - Josephs, Katherine AU - Mayers, Megan AU - Peters, Stacey AU - Stafford, Fergus AU - Bagnall, Richard D. AU - Bronicki, Lucas AU - Callewaert, Bert AU - Chahal, C. Anwar A. AU - James, Cynthia A. AU - Jarinova, Olga AU - Landstrom, Andrew P. AU - McNally, Elizabeth M. AU - Murray, Brittney AU - Muiño-Mosquera, Laura AU - Parikh, Victoria AU - Reuter, Chloe AU - Walsh, Roddy AU - Wayburn, Bess AU - Ware, James S. AU - Ingles, Jodie TI - ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel: Reappraisal of Genes associated with Hypertrophic Cardiomyopathy AID - 10.1101/2024.07.29.24311195 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.29.24311195 4099 - http://medrxiv.org/content/early/2024/08/01/2024.07.29.24311195.short 4100 - http://medrxiv.org/content/early/2024/08/01/2024.07.29.24311195.full AB - Background Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition affecting ∼1 in 500 and exhibits marked genetic heterogeneity. Previously published in 2019, 57 HCM-associated genes were curated providing the first systematic evaluation of gene-disease validity. Here we report work by the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel (HCVD-GCEP) to reappraise the clinical validity of previously curated and new putative HCM genes.Methods The ClinGen systematic gene curation framework was used to re-classify the gene-disease relationships for HCM and related syndromic entities involving left ventricular hypertrophy. Genes previously curated were included if their classification was not definitive, and if the time since curation was >2-3 years. New genes with literature assertions for HCM were included for initial evaluation. Existing genes were curated for new inheritance patterns where evidence existed. Curations were presented on twice monthly calls, with the HCVD-GCEP composed of 29 individuals from 21 institutions across 6 countries.Results Thirty-one genes were re-curated and an additional 5 new potential HCM-associated genes were curated. Among the re-curated genes, 17 (55%) genes changed classification: 1 limited and 4 disputed (from no known disease relationship), 9 disputed (from limited), and 3 definitive (from moderate). Among these, 3 (10%) genes had a clinically relevant upgrade, including TNNC1, a 9th sarcomere gene with definitive HCM association. With new evidence, two genes were curated for multiple inheritance patterns (TRIM63, disputed for autosomal dominant but moderate for autosomal recessive; ALPK3, strong for autosomal dominant and definitive for recessive). CSRP3 was curated for a semi-dominant mode of inheritance (definitive). Nine (29%) genes were downgraded to disputed, further discouraging clinical reporting of variants in these genes. Five genes recently reported to cause HCM were curated: RPS6KB1 and RBM20 (limited), KLHL24 and MT-TI (moderate), and FHOD3 (definitive).Conclusions We report 29 genes with definitive, strong or moderate evidence of causation for HCM or isolated LVH, including sarcomere, sarcomere-associated and syndromic conditions.Competing Interest StatementEMM is an advisor to Amgen, Cytokinetics, PepGen, and Tenaya, and is a founder of Ikaika Therapeutics. JW has consulted for MyoKardia, Inc., Pfizer, Foresite Labs, Health Lumen, and Tenaya Therapeutics, and receives research support from Bristol Myers-Squibb. JI receives research grant support from Bristol Myers Squibb unrelated to this work. All other authors declare no competing interests.Clinical Protocols https://clinicalgenome.org/curation-activities/gene-disease-validity/training-materials/#Documentation Funding StatementThis publication was supported in part by the National Human Genome Research Institute of the National Institutes of Health through the following grant U24HG009650. JI is the recipient of a National Heart Foundation of Australia Future Leader Fellowship (#106732). BC is a senior clinical investigator of the Research Foundation-Flanders. AB is supported by the 2022 Research Fellowship for aspiring electrophysiologists from the Swiss Heart Rhythm Foundation, and a postdoctoral research fellowship grant from the Gottfried und Julia Bangerter-Rhyner-Stiftung (Switzerland). EMM is supported by NIH HL128075, HG011169, the Leducq Foundation, and the American Heart Association. JW is supported by Medical Research Council (UK), Sir Jules Thorn Charitable Trust [21JTA], British Heart Foundation [RE/18/4/34215], and the NIHR Imperial College Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no ethics was required for this manuscriptI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are publicly available on the ClinGen public repository. https://clinicalgenome.org/working-groups/clinical-domain/cardiovascular/